IGF-DES
DES IGF-1 · IGF-1 DES · DES 1-3
IGF-DES (formally IGF-1 des(1-3)) is an N-terminal-truncated variant of insulin-like growth factor 1 (IGF-1) lacking the first three amino acids (Gly-Pro-Glu) of the native IGF-1 sequence. The 67-amino-acid truncated form retains binding affinity for the IGF-1 receptor (IGF-1R) but has dramatically reduced affinity for IGF binding proteins (IGFBP-1 through IGFBP-6). This means IGF-DES circulates as 'free' bioactive IGF-1, producing more potent local tissue effects than equivalent doses of native IGF-1 - but with a dramatically shorter plasma half-life (~20-30 minutes vs ~16-20 hours for IGF-1 LR3).
Inject directly into the subcutaneous tissue overlying the target muscle group, immediately pre-workout or intra-workout. Half-life is ~20-30 minutes - timing matters. Reconstitute with bacteriostatic water; refrigerate. Standard insulin syringe (1mL U-100) for accurate small doses.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
IGF-DES binds the insulin-like growth factor 1 receptor (IGF-1R), a receptor tyrosine kinase expressed broadly on muscle, bone, neural, and many other tissue types. Receptor activation triggers IRS-1/PI3K/Akt and MAPK signaling cascades that drive muscle protein synthesis, satellite cell activation, anti-apoptotic action, and anabolic gene expression.
Reduced IGFBP Binding
The N-terminal Gly-Pro-Glu deletion impairs binding to IGF binding proteins (IGFBP-1 through IGFBP-6). In native IGF-1, ~99% of circulating ligand is IGFBP-bound and metabolically inactive. IGF-DES circulates as 'free' bioactive ligand, producing 5-10x greater receptor activation per equimolar dose at the local injection site.
Short Plasma Half-Life
Without IGFBP binding to extend half-life, IGF-DES is rapidly cleared - plasma half-life ~20-30 minutes vs ~16-20 hours for IGF-1 LR3. This makes IGF-DES a 'pulse' agent rather than a sustained systemic IGF-1 elevator.
Local vs Systemic
The combination of high local potency and rapid clearance favors site-injection use - inject directly into target muscle for maximum local effect with minimal systemic exposure. This is the reverse profile of IGF-1 LR3 (which favors sustained systemic effect).
Anabolic Pathway
IGF-1R activation drives PI3K/Akt-mediated mTORC1 activation, increasing protein synthesis. Concurrently activates satellite cells (myogenic stem cells) for muscle hypertrophy and repair.
Insulin-Like Activity
IGF-DES retains some affinity for the insulin receptor at high doses - capable of producing hypoglycemia at supraphysiologic injection. This is a class effect of all IGF-1 variants and a relevant safety consideration.
Disulfide Stability
IGF-DES contains 3 disulfide bonds (6 Cys residues) like native IGF-1 - chemistry-incompatible with copper-conjugated peptides like GHK-Cu in the same syringe.
What to expect
First 1-2 weeks: subtle pump enhancement on training days. No obvious systemic change.
Week 2-4: cellular adaptations (satellite cell activation, local protein synthesis bursts) accumulate.
Week 4-6: peak local hypertrophy effect in trained users. Cycle off. Magnitude is modest in non-pathologic adults - not a steroid replacement.
Evidence
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Dose/route: 20-30mcg per muscle group; Subcutaneous (SubQ) - typically site-specific intramuscular SubQ near target muscle; 1-2x per training day. No checked live PubMed abstract verified this exact displayed dose, route, and frequency for the same molecule/formulation and relevant population.
Mechanism: IGF-DES binds the insulin-like growth factor 1 receptor (IGF-1R), a receptor tyrosine kinase expressed broadly on muscle, bone, neural, and many other tissue types. Receptor activation triggers IRS-1/PI3K/Akt and MAPK signaling cascades that drive muscle protein synthesis, satellite cell activation, anti-apoptotic action, and anabolic gene expression. 1. Reduced IGFBP Binding: The N-terminal Gly-Pro-Glu deletion impairs binding to IGF binding proteins (IGFBP-1 through IGFBP-6). In native IGF-1, ~99% of circulating ligand is IGFBP-bound and metabolically inactive. IGF-DES circulates as 'free' bioactive ligand, producing 5-10x greater receptor activation per equimolar dose at the local injection site. 2. Short Plasma Half-Life: Without IGFBP binding to extend half-life, IGF-DES is rapidly cleared - plasma half-life ~20-30 minutes vs ~16-20 hours for IGF-1 LR3. This makes IGF-DES a 'pulse' agent rather than a sustained systemic IGF-1 elevator. 3. Local vs Systemic: The combination of high local potency and rapid clearance favors site-injection use - inject directly into target muscle for maximum local effect with minimal systemic exposure. This is the reverse profile of IGF-1 LR3 (which favors sustained systemic effect). 4. Anabolic Pathway: IGF-1R activation drives PI3K/Akt-mediated mTORC1 activation, increasing protein synthesis. Concurrently activates satellite cells (myogenic stem cells) for muscle hypertrophy and repair. 5. Insulin-Like Activity: IGF-DES retains some affinity for the insulin receptor at high doses - capable of producing hypoglycemia at supraphysiologic injection. This is a class effect of all IGF-1 variants and a relevant safety consideration. 6. Disulfide Stability: IGF-DES contains 3 disulfide bonds (6 Cys residues) like native IGF-1 - chemistry-incompatible with copper-conjugated peptides like GHK-Cu in the same syringe.. No checked live PubMed abstract provided an exact-molecule/formulation sentence supporting this source-JSON mechanism claim.
Primary safety claim: No primary safety text present in source JSON. No checked live PubMed abstract directly verified this source-JSON safety claim at the displayed formulation, route, and regimen.
Side effects & safety
Commonly reported
- Injection site reaction (redness, mild tenderness)
- Hypoglycemic symptoms if dosed fasted (lightheadedness, sweating, hunger)
- Mild headache
- Muscle pump / soreness in injected muscle
Less common & notes
- Severe hypoglycemia at high systemic doses - eat carbs and seek care if persistent.
- Local hypertrophy asymmetry if injecting only one side.
- Theoretical malignancy promotion via IGF-1 mitogenic action - relevant for users with personal/family cancer history or suspicious findings.
- Severe injection-site reactions are rare.
- Chronic high-dose IGF-1R stimulation may theoretically accelerate aging in some pathways (rodent IGF-1-axis models suggest GH/IGF-1 excess shortens lifespan) - off-label community use lacks long-term safety data.
Pharmacokinetics
Plasma (very short - reduced IGFBP binding eliminates the half-life-extending effect of IGFBP carrier proteins)
Site-local (SubQ)
Functional local muscle effect window
subQ ~50-60%
Per dose - timing relative to training matters
Hepatic and renal proteolysis
Storage. Lyophilized vial: refrigerate (2-8°C / 36-46°F) or freeze (-20°C) for long-term storage. After reconstitution with bacteriostatic water: refrigerate, use within 14-21 days. Disulfide-containing peptide is sensitive to thermal degradation - keep cold. Light-sensitive. Do NOT shake during reconstitution - swirl gently. Discard if cloudy, discolored, or contains particulates.
Regulatory status
Not FDA-approved for any indication. Native IGF-1 (mecasermin/Increlex, Tercica) IS FDA-approved for severe primary IGFD in children but IGF-DES is a distinct truncated variant with no approval. Sold only as research chemical from peptide-supply vendors. Sale for human use is illegal under FDA regulation. WADA prohibited under class S2 (peptide hormones, growth factors). Possession is generally not criminal but distribution for human use is regulated.
Put it to work
Calculate, log & track
Open IGF-DES straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open IGF-DES in the app →Go deeper
The guide & community
The complete IGF-DES walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗